Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine : part I
Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)..
The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Arquivos de neuro-psiquiatria - 80(2022), 8 vom: 19. Aug., Seite 845-861 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Consenso da Sociedadade Brasileira de Cefaleia (SBCe) para o tratamento profilático da migrânea episódica: parte I |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.10.2022 Date Revised 15.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/s-0042-1756441 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347674976 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347674976 | ||
| 003 | DE-627 | ||
| 005 | 20231226034408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0042-1756441 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347674976 | ||
| 035 | |a (NLM)36252594 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melhado, Eliana Meire |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine |b part I |
| 246 | 3 | 3 | |a Consenso da Sociedadade Brasileira de Cefaleia (SBCe) para o tratamento profilático da migrânea episódica: parte I |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2022 | ||
| 500 | |a Date Revised 15.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). | ||
| 520 | |a The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Antidepressive Agents, Tricyclic |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 650 | 7 | |a Serotonin Uptake Inhibitors |2 NLM | |
| 650 | 7 | |a Tryptamines |2 NLM | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 700 | 1 | |a Santos, Paulo Sergio Faro |e verfasserin |4 aut | |
| 700 | 1 | |a Kaup, Alexandre Ottoni |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Aline Turbino Neves Martins da |e verfasserin |4 aut | |
| 700 | 1 | |a Roesler, Célia Aparecida de Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Piovesan, Élcio Juliato |e verfasserin |4 aut | |
| 700 | 1 | |a Sarmento, Elder Machado |e verfasserin |4 aut | |
| 700 | 1 | |a Theotonio, Giselle Oliveira Martins |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Henrique Carneiro de |e verfasserin |4 aut | |
| 700 | 1 | |a Fortini, Ida |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Jano Alves de |e verfasserin |4 aut | |
| 700 | 1 | |a Maciel Júnior, Jayme Antunes |e verfasserin |4 aut | |
| 700 | 1 | |a Segundo, João Batista Alves |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, João José Freitas de |e verfasserin |4 aut | |
| 700 | 1 | |a Speziali, José Geraldo |e verfasserin |4 aut | |
| 700 | 1 | |a Calia, Leandro Cortoni |e verfasserin |4 aut | |
| 700 | 1 | |a Barea, Liselotte Menke |e verfasserin |4 aut | |
| 700 | 1 | |a Queiroz, Luiz Paulo |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Marcio Nattan Portes |e verfasserin |4 aut | |
| 700 | 1 | |a Figueiredo, Marcos Ravi Cerqueira Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Maria Eduarda Nobre de Magalhães |e verfasserin |4 aut | |
| 700 | 1 | |a Peres, Mário Fernando Prieto |e verfasserin |4 aut | |
| 700 | 1 | |a Jurno, Mauro Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Peixoto, Patrícia Machado |e verfasserin |4 aut | |
| 700 | 1 | |a Kowacs, Pedro André |e verfasserin |4 aut | |
| 700 | 1 | |a Rocha-Filho, Pedro Augusto Sampaio |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira Filho, Pedro Ferreira |e verfasserin |4 aut | |
| 700 | 1 | |a Silva-Neto, Raimundo Pereira |e verfasserin |4 aut | |
| 700 | 1 | |a Fragoso, Yara Dadalti |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arquivos de neuro-psiquiatria |d 1945 |g 80(2022), 8 vom: 19. Aug., Seite 845-861 |w (DE-627)NLM000154334 |x 1678-4227 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2022 |g number:8 |g day:19 |g month:08 |g pages:845-861 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0042-1756441 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2022 |e 8 |b 19 |c 08 |h 845-861 | ||